Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer
Authors
Keywords
-
Journal
Nature Communications
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-05-09
DOI
10.1038/s41467-022-30142-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Statin Exposure and Risk of Heart Failure After Anthracycline‐ or Trastuzumab‐Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study
- (2021) Husam Abdel‐Qadir et al. Journal of the American Heart Association
- Unlocking the potential of antibody–drug conjugates for cancer therapy
- (2021) Joshua Z. Drago et al. Nature Reviews Clinical Oncology
- Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab
- (2021) Otto Metzger Filho et al. Cancer Discovery
- Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity Through Redistribution of Phosphorylated Caveolin-1
- (2020) Vineesh Indira Chandran et al. MOLECULAR CANCER RESEARCH
- Acquired resistance to trastuzumab/pertuzumab or to T‐DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728
- (2020) Hiroki Irie et al. CANCER SCIENCE
- Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies
- (2020) Hui Yi Chew et al. CELL
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
- (2020) Kohei Shitara et al. NEW ENGLAND JOURNAL OF MEDICINE
- HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
- (2020) Bob T. Li et al. Cancer Discovery
- Acute statin treatment improves antibody accumulation in EGFR- and PSMA-expressing tumors
- (2020) Patricia M.R. Pereira et al. CLINICAL CANCER RESEARCH
- Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
- (2020) Daniel V.T. Catenacci et al. Cancer Discovery
- HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.
- (2019) Otto Metzger Filho et al. JOURNAL OF CLINICAL ONCOLOGY
- Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors
- (2019) Patricia MR Pereira et al. JOURNAL OF NUCLEAR MEDICINE
- HER2-targeted therapies — a role beyond breast cancer
- (2019) Do-Youn Oh et al. Nature Reviews Clinical Oncology
- Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
- (2019) Jacqulyne P. Robichaux et al. CANCER CELL
- Immune modulatory effects of statins
- (2018) Robert Zeiser IMMUNOLOGY
- Metformin-induced caveolin-1 expression promotes T-DM1 drug efficacy in breast cancer cells
- (2018) Yuan-Chiang Chung et al. Scientific Reports
- Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
- (2018) Josep Tabernero et al. LANCET ONCOLOGY
- Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy
- (2018) Patrícia M. R. Pereira et al. Nature Communications
- EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer
- (2018) Francisco Sanchez-Vega et al. Cancer Discovery
- Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
- (2017) Peter C Thuss-Patience et al. LANCET ONCOLOGY
- Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)
- (2017) Matthew Sung et al. MOLECULAR CANCER THERAPEUTICS
- Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer
- (2017) Yelena Y. Janjigian et al. Cancer Discovery
- Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT
- (2016) G. A. Ulaner et al. JOURNAL OF NUCLEAR MEDICINE
- Caveolin-1 in the regulation of cell metabolism: a cancer perspective
- (2016) Zeribe Chike Nwosu et al. Molecular Cancer
- Hypoxia regulates global membrane protein endocytosis through caveolin-1 in cancer cells
- (2016) E. Bourseau-Guilmain et al. Nature Communications
- Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial
- (2015) G. Gebhart et al. ANNALS OF ONCOLOGY
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
- (2015) Donavan T. Cheng et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out Immunocompromised mice
- (2015) Christian Wetterauer et al. PROSTATE
- Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1)
- (2015) Yuan-Chiang Chung et al. PLoS One
- Human epidermal growth factor receptor 2 testing in gastric cancer: Recommendations of an Asia-Pacific Task Force
- (2014) Kyoung-Mee Kim et al. Asia-Pacific Journal of Clinical Oncology
- Monitoring Afatinib Treatment in HER2-Positive Gastric Cancer with 18F-FDG and 89Zr-Trastuzumab PET
- (2013) Y. Y. Janjigian et al. JOURNAL OF NUCLEAR MEDICINE
- HER-2/neu Mediates Oncogenic Transformation via Altered CREB Expression and Function
- (2013) A. Steven et al. MOLECULAR CANCER RESEARCH
- Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model
- (2013) YORIKO YAMASHITA-KASHIMA et al. ONCOLOGY REPORTS
- Identification of Caveolin-1 as a Potential Causative Factor in the Generation of Trastuzumab Resistance in Breast Cancer Cells
- (2013) Sreeja C Sekhar et al. Journal of Cancer
- Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
- (2012) Holbrook E. Kohrt et al. JOURNAL OF CLINICAL INVESTIGATION
- HER2 testing in gastric cancer: a practical approach
- (2012) Josef Rüschoff et al. MODERN PATHOLOGY
- Human Solid Tumor Xenografts in Immunodeficient Mice Are Vulnerable to Lymphomagenesis Associated with Epstein-Barr Virus
- (2012) Kui Chen et al. PLoS One
- ErbB2 Trafficking and Degradation Associated with K48 and K63 Polyubiquitination
- (2010) Corina Marx et al. CANCER RESEARCH
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Inhibition of cholesterol biosynthesis disrupts lipid raft/caveolae and affects insulin receptor activation in 3T3-L1 preadipocytes
- (2009) Jana Sánchez-Wandelmer et al. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
- Standardized methods for the production of high specific-activity zirconium-89
- (2009) Jason P. Holland et al. NUCLEAR MEDICINE AND BIOLOGY
- CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers
- (2008) L M Smith et al. BRITISH JOURNAL OF CANCER
- IL-15 trans-presentation promotes human NK cell development and differentiation in vivo
- (2008) Nicholas D. Huntington et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Correlation between NK function and response to trastuzumab in metastatic breast cancer patients
- (2008) Alessandra Beano et al. Journal of Translational Medicine
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started